Search results for " Parenteral"

showing 10 items of 39 documents

Plan Nacional sobre el Sida. Prevención en usuarios de drogas por vía parenteral

2002

En esta exposición se constata como el primer plan estratégico frente al VIH/Sida aprobado en España ha resultado ser positivo en sus resultados, por lo que el Nuevo Plan Multisectorial para el periodo 2001 2005 se desarrolla e intenta optimizar den¬tro de su primera orientación básica reforzando su carácter preventivo y su dimensión multifactorial. En las estrategias de reducción de daños respecto sobre todo a la dispensación de material de inyección estéril y preservativos se ha observado una buena colaboración tanto por parte de los usuarios como de los centros dispensadores y profesionales. Sin embargo en el nuevo Plan se amplia esta estrategia y se completa en el contexto de otras enfe…

:PSICOLOGÍA::Psicofarmacología [UNESCO]:PSICOLOGÍA [UNESCO]Usuarios de drogas por vía parenteral (UDVP) Reducción de daños Venopunción hi¬giénica Prescripción controlada de Heroína Detección precoz de infección VIH.UNESCO::PSICOLOGÍAUNESCO::PSICOLOGÍA::Psicofarmacología
researchProduct

Unique Characteristics of the Intestinal Immune System as an Inductive Site after Antigen Reencounter

2004

Background Immunization prepares the body for a reencounter with the microbe. Information on the targeting of immune effector cells during secondary immune response--that is, lymphocyte homing--is scarce. In the present study, the homing potentials of lymphocytes are examined after antigen reencounter at mucosal versus nonmucosal sites. Methods Orally or parenterally immunized volunteers were reimmunized orally or parenterally with Salmonella typhi Ty21a, and the expression of the gut homing receptor (HR), alpha(4)beta(7), and of the peripheral lymph node HR, L-selectin, was investigated in circulating antigen-specific antibody-secreting cells (ASCs). Lymphocytes were sorted by HR expressio…

AdultMaleLymphocyteReceptors Lymphocyte HomingAdministration OralPriming (immunology)chemical and pharmacologic phenomenaLymphocyte migration into lymph nodeLymphocyte Activation03 medical and health sciences0302 clinical medicineImmune systemAntigenmedicineHumansImmunology and AllergyInfusions ParenteralAntibody-Producing CellsLymphocyte homing receptor030304 developmental biology0303 health sciencesbiologyDrug Administration RoutesTyphoid-Paratyphoid VaccinesSalmonella typhi3. Good healthIntestinesInfectious Diseasesmedicine.anatomical_structureImmune SystemImmunologybiology.proteinFemaleL-selectin030215 immunologyHoming (hematopoietic)The Journal of Infectious Diseases
researchProduct

Pharmacokinetics of triamterene after i.v. administration to man: determination of bioavailability.

1983

With a new formulation, which made intravenous infusion of triamterene (TA) possible, plasma levels and urinary excretion rates of TA and its main metabolite (OH-TA-ester) were measured in a randomized, cross-over trial in 6 healthy volunteers given triamterene 10 mg i.v. and 50 mg p.o. TA and OH-TA-ester were determined by densitometric measurement of native fluorescence after thin layer chromatography. Distribution volumes of the central compartment of TA and OH-TA-ester were 1.49 l/kg and 0.11 l/kg, respectively. Terminal half-lives were 255 min for TA and 188 min for OH-TA-ester after i.v. administration. For TA total plasma clearance was 4.5 l/min and renal plasma clearance 0.22 l/kg. …

AdultMaleMetabolitemedicine.medical_treatmentBiological AvailabilityAbsorption (skin)PharmacologyFirst pass effectchemistry.chemical_compoundPharmacokineticsmedicineHumansPharmacology (medical)Infusions ParenteralPharmacologyTriamtereneChromatographyGeneral MedicineThin-layer chromatographyBioavailabilityKineticschemistryFemaleDiureticmedicine.drugTriamtereneEuropean journal of clinical pharmacology
researchProduct

Lorcainide; II. Plasma concentration-effect relationship

1979

AdultMalePharmacologyChromatographybusiness.industryBenzeneacetamidesAdministration OralArrhythmias CardiacIn Vitro TechniquesMiddle AgedLorcainideElectrocardiographyPiperidinesInjections IntravenousPlasma concentrationmedicineHumansAcetanilidesFemaleInfusions ParenteralPharmacology (medical)businessAnti-Arrhythmia AgentsAgedmedicine.drugClinical Pharmacology & Therapeutics
researchProduct

Gonadotropin and Testosterone Secretion in Normal Human Males After Stimulation With Gonadotropin-Releasing Hormone (Gnrh) or Potent Gnrh Analogs Usi…

1978

Gonadotropin-releasing hormone (GnRH) and some potent long-acting GnRH analogs, applied by different routes of administration, were tested in six healthy human males. The effects on gonadotropin secretion were compared with the one after intravenous (i.v.) bolus injection of 25 microgram of GnRH. The net increase of luteinizing hormone (deltaLH) in serum produced by 25 microgram of GnRH i.v. was matched by subcutaneous (s.c.) injection of 100 microgram of GnRH, dissolved in 20% gelatin or without gelatin; 5 microgram of D-Ser (TBU)6-des-Gly10-GnRH-ethylamide i.v.; 5 microgram of D-Leu6-des-Gly10-GnRH-ethylamide i.v.; and 50 microgram of D-Trp6-des Gly10-GnRH-ethylamide given pernasally (p.n…

AdultMaleendocrine systemmedicine.medical_specialtyTime Factorsmedicine.drug_classMicrogramStimulationGonadotropin-releasing hormoneGonadotropin-Releasing HormoneInternal medicinemedicineHumansInfusions ParenteralTestosteroneAdministration IntranasalChemistryObstetrics and GynecologyLuteinizing HormoneHormonesGonadotropin secretionEndocrinologyReproductive MedicineInjections IntravenousNasal administrationFollicle Stimulating HormoneGonadotropinLuteinizing hormonePituitary Hormone-Releasing Hormoneshormones hormone substitutes and hormone antagonistsHormoneFertility and Sterility
researchProduct

Effect of intravenous flecainide on atrial vulnerability in man.

1985

Sixteen patients were investigated by means of programmed atrial stimulation at 2 different driving rates: 100/min and 120/min. All patients had an increased atrial vulnerability at both driving rates. After the administration of intravenous flecainide (1 mg/kg bodyweight as a bolus, followed by the same amount infused over a period of 20 minutes), the increased vulnerability was abolished in 11 and 9 patients, respectively. In the remaining patients the rate of induced atrial tachyarrhythmia decreased. These findings correlate with a significant prolongation of the effective refractory period of the right atrium and a corresponding significant shortening of its relative refractory period. …

AdultMalemedicine.medical_specialtyAdolescentRefractory Period ElectrophysiologicalRefractory periodElectrocardiographyBolus (medicine)PiperidinesInternal medicinemedicineHumansPharmacology (medical)Infusions ParenteralHeart AtriaFlecainideAgedFlecainidemedicine.diagnostic_testbusiness.industryAtrial vulnerabilityEffective refractory periodAtrial fibrillationArrhythmias CardiacMiddle Agedmedicine.diseaseAtrial FlutterAnesthesiaCardiologyFemalebusinessElectrocardiographyAnti-Arrhythmia AgentsAtrial fluttermedicine.drugDrugs
researchProduct

No change in apolipoprotein AI metabolism when subcutaneous insulin infusion is replaced by intraperitoneal insulin infusion in type 1 diabetic patie…

2006

In type 1 diabetic patients, the replacement of subcutaneous insulin infusion by intraperitoneal insulin infusion restores the normal physiological gradient between the portal vein and the peripheral circulation, which is likely to modify HDL metabolism. This stable isotope kinetic study was designed to compare HDL apolipoprotein (apo) AI metabolism in seven type 1 diabetic patients first treated by continuous subcutaneous insulin infusion by an external pump and then 3 months after the beginning of intraperitoneal insulin infusion by an implantable pump. Glycaemic control was comparable under subcutaneous and intraperitoneal insulin infusion (HbA1c=7.34+/-0.94% versus 7.24+/-1.00%, NS). HD…

AdultMalemedicine.medical_specialtyApolipoprotein Bmedicine.medical_treatmentCarbon Compounds InorganicSulfidesAdministration Cutaneouschemistry.chemical_compoundInsulin Infusion SystemsDiabetes mellitusInternal medicinemedicineHumansInsulinInfusions ParenteralPancreatic hormoneType 1 diabetesTriglyceridebiologyApolipoprotein A-Ibusiness.industryCholesterolInsulinMetabolismMiddle Agedmedicine.diseaseKineticsEndocrinologyDiabetes Mellitus Type 1chemistrybiology.proteinFemaleCardiology and Cardiovascular MedicinebusinessLipoproteins HDLAtherosclerosis
researchProduct

Investigation into isoprenaline resistance in patients with obstructive lung disease

1974

12 patients with chronic obstructive lung disease have been studied in an investigation regarding the causes of resistance to isoprenaline. The effects of repeated intravenous doses of 10 µg isoprenaline were assessed by cross over comparison before and after infusions of isoprenaline and a placebo; the infusions lasted for 35 to 40 min and the amount of isoprenaline infused was 0.5 µg/min. Total resistance, thoracic gas volume (whole-body plethysmography) and heart rate (ECG) were measured. No decrease in bronchospasmolytic or positive chronotopic effects on single isoprenaline injections could be demonstrated after prolonged infusions of isoprenaline.

AdultMalemedicine.medical_specialtyDrug ResistanceDrug resistancePlaceboPlacebosElectrocardiographyHeart RateIsoprenalineInternal medicineHeart ratemedicineHumansPlethysmographInfusions ParenteralPharmacology (medical)Lung Diseases ObstructiveAgedPlethysmography Whole BodyAsthmaPharmacologyAnalysis of VarianceClinical Trials as Topicbusiness.industryAirway ResistanceIsoproterenolGeneral MedicineMiddle Agedmedicine.diseaseStimulation ChemicalObstructive lung diseaseAirway ObstructionBronchodilatationAnesthesiaInjections IntravenousCardiologyFemalebusinessmedicine.drugEuropean Journal of Clinical Pharmacology
researchProduct

Macroamylasaemia after treatment with hydroxyethyl starch

1977

After infusion of 500 ml of 6% hydroxyethyl starch into fifty-four patients an increase of serum amylase was observed which in fifty-one cases exceeded the upper limit of normal (190 U/l). In most cases serum amylase reached twice the basal value. Renal function influenced the duration of the increase in serum amylase, but not the maximum increase (201+/-15 U/l; mean+/-SEM). In patients with advanced renal failure (glomerular filtration rate (GFR) = 2-10 ml/min) serum amylase was still markedly elevated after 72 h (298+/-24 U/l; mean+/-SEM). In patients with normal renal function (GFR greater than 90 ml/min) serum amylase decreased to 183+/-40 U/l (mean+/-SEM) within 72 h without reaching b…

AdultMalemedicine.medical_specialtyPancreatic diseaseClinical BiochemistryRenal functionUrineIn Vitro TechniquesHydroxyethyl starchBiochemistryHydroxyethyl Starch DerivativesExcretionBasal (phylogenetics)Renal DialysisInternal medicinemedicineHumansInfusions ParenteralAmylaseLipasePancreasbiologyChemistryStarchGeneral MedicineMiddle Agedmedicine.diseaseEndocrinologyAmylasesHypertensionChromatography Gelbiology.proteinKidney Failure ChronicFemaleGlomerular Filtration Ratemedicine.drugEuropean Journal of Clinical Investigation
researchProduct

Feasibility of a modified outpatient regimen of intravenous/intraperitoneal chemotherapy in optimally debulked stage III ovarian cancer patients: a G…

2011

Objectives: The objective of the study was to assess the feasibility, toxicity, and reasons for early discontinuation of a modified outpatient intraperitoneal/intravenous (IP/IV) chemotherapy regimen for the treatment of patients with optimally debulked stage III ovarian cancer. Methods: Between February 2006 and November 2008, 51 consecutive patients from Institutions of the Spanish Ovarian Cancer Group (GEICO) were treated with a modified outpatient IP chemotherapy regimen. Patients received IV paclitaxel 175 mg/m2 over 3 hours on day 1, followed by IP cisplatin 100 mg/m2 (or 75 mg/m2 according to the principal investigator9s criteria) on day 2. On day 8, patients received IP paclitaxel 6…

Adultmedicine.medical_specialtyPaclitaxelmedicine.medical_treatmentNeutropeniaCarcinoma Ovarian EpithelialDrug Administration ScheduleAntineoplastic Combined Chemotherapy ProtocolsOutpatientsMedicineHumansInfusions ParenteralNeoplasms Glandular and EpithelialProspective StudiesProspective cohort studyInfusions IntravenousAgedNeoplasm StagingStage III Ovarian CancerOvarian NeoplasmsChemotherapybusiness.industryObstetrics and GynecologyMiddle Agedmedicine.diseaseChemotherapy regimenSurgeryClinical trialRegimenTreatment OutcomeOncologySpainFeasibility StudiesFemaleCisplatinbusinessOvarian cancerInternational journal of gynecological cancer : official journal of the International Gynecological Cancer Society
researchProduct